The UAB Cancer Center offers patients with advanced and rare cancer, including those with any stage of pancreatic and brain cancer, the opportunity to have no-cost tumor profiling, and patients may be matched with an appropriate clinical trial or recommend use of an FDA-approved drug.
The annual symposium May 15 will provide help and support for cancer patients and survivors.
The first target for the UAB spinoff Incysus Ltd. will be glioblastoma. Incysus has just received a European patent for its innovative approach to fighting cancer.
UAB announces a partnership with Guideway Care to expand the reach of UAB’s proven cancer navigation program, Patient Care Connect, to patients nationally.
UAB Comprehensive Cancer Center’s Fiesta Ball on May 5 will support the work of young cancer research scientists and patient and family services.
Unusual case of teen patient diagnosed with colorectal cancer receives innovative first-in-human clinical trial at UAB, reflecting a unique story of cancer and hope.
Cycliad, a community cycling event, will be held March 25 in Birmingham to benefit cancer patients at UAB.
Failure of hormone deprivation therapy used to slow prostate cancer in patients leads to castration-resistant prostate cancer, a lethal form of advanced disease with limited treatment options. Endostatin, used in combination therapy, may help delay onset of castration-resistant disease.
March is Colorectal Cancer Awareness Month, and UAB kicks it off with an inaugural Colon on the Green event March 3.
A UAB study shows specialized treatment sites contribute to better survival rates for those with acute leukemia.